Thermo Fisher Scientific (TMO) saw its stock price dip roughly 1% after announcing a $3.8 billion bond deal to fund its acquisition of clinical-trial data specialist Clario. This move raises questions about the company’s new leverage and the progress of the regulator-sensitive deal amidst shifting rates. Investors are also looking ahead to a packed holiday week with U.S. retail sales data and Federal Reserve minutes, both of which could impact interest rate expectations.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Thermo Fisher (TMO) stock price dips after $3.8 billion bond deal — what to watch in the holiday week ahead
Thermo Fisher Scientific (TMO) saw its stock price dip roughly 1% after announcing a $3.8 billion bond deal to fund its acquisition of clinical-trial data specialist Clario. This move raises questions about the company’s new leverage and the progress of the regulator-sensitive deal amidst shifting rates. Investors are also looking ahead to a packed holiday week with U.S. retail sales data and Federal Reserve minutes, both of which could impact interest rate expectations.